Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001172661-25-001247
Filing Date
2025-02-14
Accepted
2025-02-14 17:06:48
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9025
  Complete submission text file 0001172661-25-001247.txt   11005
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Subject) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-48089 | Film No.: 25630694
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022
Business Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022 (212) 231-4932
ARMISTICE CAPITAL, LLC (Filed by) CIK: 0001601086 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A